On-Demand Webinar: From MedChem to GMP, DS & DP Choices That Shape IND Timelines

Scaling up from medicinal chemistry to clinical manufacturing can introduce hidden risks that impact timelines, API quality, and regulatory success.

In this webinar, we explore the critical challenges faced when transitioning from early medicinal chemistry routes to scale, highlighting how overlooked decisions around impurity control, solid form, and process design can lead to costly delays and rework.

Dr Mark Anstiss, Head of Drug Substance Operations, and Dr Thomas Nunns, Director, Drug Development Consultant, will demonstrate how integrating drug substance and formulation development early can identify risks sooner, reduce timeline creep, and support confident progression to IND and first-in-human studies.

Download the webinar today to hear what our experts have to say!